Identity for NAD+ rests on orthogonal evidence: accurate mass near m/z 664.116 for the protonated molecule, MS/MS fragments including adenine at 136.062, retention matching a reference standard on a method that separates NADH, NADP and the α anomer, and a 259 nm UV maximum. Purity percentage is a separate claim.
- A purity percentage describes proportion of detector response and establishes nothing about which compound the main peak is.
- NAD+ free acid is C21H27N7O14P2, average mass 663.43, monoisotopic 663.1091, CAS 53-84-9, with the protonated species observed near m/z 664.116.
- The adenine fragment at m/z 136.062 is shared by every adenine nucleotide, so a single MRM transition is weak identity evidence.
- The α anomer of NAD has identical mass and fragmentation and can only be excluded by chromatographic resolution, NMR or a stereospecific enzymatic assay.
- Absorbance at 340 nm distinguishes reduced from oxidized pyridine nucleotide, using the 6,220 M⁻¹cm⁻¹ extinction coefficient.
- A stated milligram content is uninterpretable without the salt form, counter-ion and water content on the same certificate.
Purity and identity answer different questions
A certificate that reads 99.2% is making a statement about proportion. Of the material that the detector saw, under the conditions the method imposed, 99.2% of the response came from one peak. That number says nothing at all about which compound produced the peak. A vial of nicotinamide mononucleotide can be 99.5% pure nicotinamide mononucleotide and still be mislabelled NAD+, and the chromatogram will look immaculate.
This is not a hypothetical failure mode. The nicotinamide family sold into research supply chains contains at least five compounds that a casual reader treats as interchangeable: nicotinamide itself, nicotinamide riboside, nicotinamide mononucleotide, NAD in its oxidized and reduced forms, and the phosphorylated NADP pair. They differ in mass by amounts a mass spectrometer resolves without effort. They also differ in price, which is the part that creates the incentive.
Identity confirmation is the separate exercise of establishing that the principal component is the compound named on the label. It takes at least two independent lines of evidence, chosen so that a substitution which fools one is caught by the other. Chromatography alone will not do it. Mass alone will not do it either, for reasons that become obvious once you look at what the mass actually distinguishes.
- Accurate mass near m/z 664.116 with a two-phosphorus isotope pattern
- Two MS/MS transitions with a ratio matched to a standard in the same run
- Retention and co-injection against a reference standard on a method that resolves the family
- UV maximum near 259 nm, constant across the peak, with the 340 nm check for redox state
- NMR or enzymatic activity for the anomeric configuration that mass cannot see
The molecule being proved
NAD+ is a dinucleotide. A nicotinamide riboside unit and an adenosine unit are joined through a 5',5'-pyrophosphate bridge. The nicotinamide nitrogen is quaternary and carries a positive charge in the oxidized form, which is why the species is written with the plus sign; the free acid as usually drawn is an inner salt with formula C21H27N7O14P2, average mass 663.43 and monoisotopic mass 663.1091. The CAS registry number for the free acid is 53-84-9.
Two structural details drive most of the analytical work. The glycosidic linkage at the nicotinamide ribose is β in the biologically relevant compound, and the α anomer is a real, documented species with the same elemental composition and the same fragmentation. No mass measurement will separate them. Second, the redox state sits at C4 of the nicotinamide ring, so NADH differs from NAD+ by two hydrogens and 2.016 Da, which is trivial to see by mass but easy to overlook if nobody looked.
Salt form matters for a different reason. Material is supplied as free acid, as a mono- or disodium salt, and often as an unspecified hydrate. The disodium salt of the free acid has a formula weight near 707.4, so a vial containing 100 mg of disodium salt contains roughly 93.8 mg of NAD free-acid equivalent before any water content is subtracted. That is a documentation question rather than an identity question, but it lands in the same paragraph of the same certificate and it changes concentration arithmetic by about six percent.
Mass spectrometry: what the numbers settle
Electrospray in positive mode gives the protonated species near m/z 664.116; negative mode gives m/z 662.102. On an instrument capable of a few parts per million, that measurement plus an isotope pattern consistent with two phosphorus atoms and seven nitrogens is a strong constraint on elemental composition. It is not yet a structure.
Fragmentation adds the structural layer. The transitions reported for NAD+ in positive mode are dominated by cleavages around the pyrophosphate and the nicotinamide glycosidic bond: loss of neutral nicotinamide (122.048) to give m/z 542.07, formation of protonated ADP at m/z 428.04, and the adenine ion at m/z 136.062. In negative mode the analogous pair is m/z 540.05 and the AMP fragment at 346.06.
Read that list carefully and the limitation appears. The adenine fragment at 136.062 is produced by every adenine nucleotide in the building: ATP, ADP, AMP, NADH, NADP+, cyclic ADP-ribose. A single-transition MRM method monitoring 664 to 136 is confirming the precursor mass and a very common daughter, which is thin evidence to hang an identity claim on. Two transitions with a consistent ratio is the working minimum, and the ratio should be recorded against a reference standard run in the same sequence rather than quoted from a paper.
| Compound | Formula (neutral or cation) | Monoisotopic mass | Δ from NAD+ |
|---|---|---|---|
| Nicotinamide | C6H6N2O | 122.048 | -541.061 |
| Nicotinamide riboside (cation) | C11H15N2O5+ | 255.098 | -408.011 |
| Nicotinamide mononucleotide | C11H15N2O8P | 334.057 | -329.052 |
| NAD+ (free acid, inner salt) | C21H27N7O14P2 | 663.109 | reference |
| NADH | C21H29N7O14P2 | 665.125 | +2.016 |
| NADP+ | C21H28N7O17P3 | 743.076 | +79.966 |
| α-NAD anomer | C21H27N7O14P2 | 663.109 | 0.000 |
The last row is the one that matters. Every other substitution in that table is caught by an accurate-mass measurement in a single injection. The anomer is invisible to mass spectrometry in every mode, at every resolution, and has to be handled by separation or by a method sensitive to stereochemistry.
Chromatography carries what mass cannot
NAD+ is small, doubly charged over most of the accessible pH range and very polar. On a plain C18 column with a mostly aqueous mobile phase it elutes at or near the void, which is the same place the nicotinamide degradation products and the inorganic front sit. A retention time near t0 resolves nothing and identifies nothing.
Two routes are conventional. Ion-pair reversed phase, using a tetraalkylammonium or alkylamine additive to give the analyte something hydrophobic to travel with, produces good retention and good resolution of the family. It also contaminates the source and suppresses ionization, so labs that need LC-MS usually keep an ion-pair method for UV work and a separate HILIC or amide-phase method for the mass detector. HILIC retains the polar analytes by a mechanism that is genuinely different from reversed phase, which is helpful when the point is orthogonality.
Whichever column is used, the identity claim depends on three things being documented rather than assumed. First, the retention of the sample peak against a reference standard injected in the same run, not a value carried over from a validation report. Second, a co-injection or spike showing a single symmetric peak when standard and sample are mixed, which is the cheapest test for a coincidental match. Third, evidence that the method actually resolves the plausible confounders, including the α anomer, since a method that cannot separate them cannot be used to exclude them. USP General Chapter <621> sets the system-suitability framework that makes such retention comparisons defensible, and ICH Q2(R2) is the document that defines specificity as something you demonstrate rather than declare.
The trap in the purity number is response factor. Area percent at 260 nm weights each species by its molar absorptivity at that wavelength. Nicotinamide absorbs there far more weakly than the intact dinucleotide, so a nicotinamide impurity present at several percent by mass shows up as a much smaller area percent. Area percent and mass percent are not the same quantity, and a certificate that reports one while implying the other is being loose.
The UV evidence, including the 340 nm check
The adenine chromophore gives NAD+ an absorbance maximum near 259 nm with a molar absorptivity around 18,000 M⁻¹cm⁻¹. That is enough for a spectral check: a diode-array trace across the peak should show the expected maximum and should be constant across the peak, since a shifting spectrum from front to back is direct evidence of co-elution.
The more useful measurement is at 340 nm. Reduced pyridine nucleotides absorb there and oxidized ones do not; the extinction coefficient of 6,220 M⁻¹cm⁻¹ established by Horecker and Kornberg in 1948 is still the value in use. An A340/A259 ratio therefore reports on redox state, and a sample of NAD+ carrying meaningful NADH will declare itself in a cuvette in under a minute. The reverse check applies to NADH material.
Concentrations for UV work need thought, because the numbers are large. At 1 mg/mL the free acid is about 1.51 mM, which in a 1 cm cell gives an A259 near 27. Anything read at that level is off scale on most instruments and meaningless. Dilution into a defined buffer, recorded with the dilution factor, is part of the measurement rather than a preliminary to it. The vial concentration calculator covers the mg-per-mL arithmetic for a given vial and diluent volume.
Where NMR and the enzymatic assay earn their place
NMR is the method that answers the anomer question directly. The 1H spectrum of NAD+ has a well-separated set of nicotinamide ring resonances downfield of 8 ppm and two anomeric protons near 6 ppm, and the chemical shift and coupling of the nicotinamide anomeric proton differ between the α and β forms. The 31P spectrum shows the two-signal pattern of a pyrophosphate bridge, which also happens to be a quick way to notice that you are looking at a monophosphate instead. Quantitative 1H NMR against a certified internal standard gives an absolute assay figure that is independent of chromatographic response factors, which is why it appears on the better certificates as a separate line from HPLC purity.
The other stereospecific test is biochemical. Yeast alcohol dehydrogenase accepts β-NAD+ and not the α anomer, and the reaction is followed as an increase in absorbance at 340 nm as NADH forms. A material that gives the right mass, the right retention and no enzymatic activity is telling you something specific. This kind of functional confirmation is unusual on commercial certificates and worth asking about when the intended work depends on cofactor activity rather than on the molecule merely being present.
Reading the certificate
Certificates for research chemicals vary from a full analytical package to a single line of text under a letterhead. The useful ones are legible in the same way a lab notebook is legible: each test named, each condition stated, each result attributable to the lot in front of you.
| Entry | Establishes | Does not establish |
|---|---|---|
| HPLC purity, area % at stated wavelength | Relative proportion of the main peak under those conditions | What the main peak is; mass percent; non-absorbing impurities |
| Accurate mass or LC-MS | Elemental composition consistent with C21H27N7O14P2 | Anomeric configuration; redox state if only one mode was run |
| MS/MS with two transitions and ratio | Structural fragments consistent with a nicotinamide-adenine dinucleotide | Stereochemistry; discrimination from isomers of identical mass |
| 1H and 31P NMR | Connectivity, phosphate arrangement, anomeric configuration | Trace-level impurities below the detection limit of the experiment |
| qNMR or titrimetric assay | Content of the named substance by mass | Identity on its own, without the spectral assignment |
| Water content (Karl Fischer or loss on drying) | How much of the vial mass is water | Anything about the remaining mass |
| Salt form and counter-ion | Basis for free-acid equivalent calculations | Purity of the active portion |
| Lot number, manufacture date, analyst, method reference | Traceability of the document to the material | Nothing analytical, and it is still the entry most often missing |
Red flags, in rough order of how often they appear. A purity figure with no method, wavelength or column stated. A certificate with no lot number, or a lot number that does not match the vial label. A single MS transition presented as identity confirmation. Silence on salt form combined with a stated milligram content. Text that has clearly been copied between products, which shows up as a wavelength or retention time that makes no sense for the compound named.
And identical numbers across multiple lots, which is a template rather than a measurement. What a supplier is prepared to send in writing before a purchase is a reasonable proxy for what its quality system does; the quality standard page sets out the documentation we hold ourselves to, and cost per mg is the arithmetic that makes salt form and water content visible in price comparisons.
Sample preparation can create the impurity you then report
NAD+ is not indifferent to the solution you put it in. The oxidized form is unstable toward base, degrading through cleavage at the nicotinamide riboside linkage to give nicotinamide and ADP-ribose; the reduced form has the opposite preference and is degraded by acid. A sample dissolved in an unbuffered diluent that drifted alkaline, then left in an autosampler at ambient temperature overnight, can present an impurity profile generated entirely between weighing and injection.
Two practices contain this. Prepare in a defined buffer near neutral pH, recording the buffer and its lot, and inject promptly or hold the tray chilled. And run a preparation blank alongside, so that any peak appearing in both the blank and the sample is attributable to the diluent rather than the material. Choice of diluent belongs in the record for the same reason the lot number does; the note on bacteriostatic water covers what a preserved aqueous diluent contributes and what it does not.
Hygroscopicity is the quieter version of the same problem. These solids pick up water from room air, and a vial opened repeatedly in a humid lab will read differently on Karl Fischer at the end of a project than at the start. If a gravimetric assay depends on the dry mass, the water figure has to be current rather than inherited from the certificate.
Regulatory position
NAD+ occurs endogenously and is sold in several regulatory categories depending on jurisdiction and form. In the United States, FDA has evaluated nicotinamide adenine dinucleotide among the bulk drug substances nominated for use in pharmacy compounding and has placed it in the category of substances it considers to raise significant safety risks; the agency's published list is the authoritative current statement and should be checked directly rather than quoted second-hand. Material supplied as a laboratory reagent is not manufactured to pharmaceutical quality standards for sterility, endotoxin or lot release, and a certificate of analysis covering identity and purity is a narrower claim about a different kind of product.
Status verified 26 August 2026.
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR PERSONAL, MEDICAL, DIAGNOSTIC, THERAPEUTIC, OR RECREATIONAL USE.
What is NAD+ studied for?
Published research on NAD+ investigates the areas below, which is a different question from what NAD+ will do for anyone, a claim about a living system that nothing on this site is sold for.
What it is. Nicotinamide adenine dinucleotide, a helper molecule rather than a peptide.
What the research looks at. A very large basic-science record on how cells make energy, on oxidation and reduction, and on enzymes. Most of it is about what the molecule does inside cells rather than about any product sold in a vial.
How it is thought to work. It carries hydrogen back and forth in the reactions that make energy, switching between two forms, and it is also used up as raw material by two families of enzymes, the sirtuins and the PARPs. Its basic biochemistry is textbook material and nobody disputes it.
What is not established. Well-understood biochemistry says nothing about any particular preparation in a vial. NAD+ is chemically different from the precursors it is often lumped in with, and material of this kind pulls in water from the air and degrades in light, which makes the handling paperwork matter more than usual.
The full record, including the certificate for the lot in stock, is on the NAD+ product page.
Common questions
Can a purity percentage confirm that a vial contains NAD+?
Which single test is the strongest identity evidence?
Why does the 340 nm absorbance matter for NAD+?
How is the α anomer detected if it has the same mass?
What does salt form change on a certificate?
Should sample preparation conditions appear in the record?
More documentation guides
Sources
- PubChem record for NAD+ (National Library of Medicine). Establishes molecular formula C21H27N7O14P2, average and monoisotopic mass, and CAS registry number 53-84-9 for the free acid, together with the related NADH, NADP and nicotinamide entries used in the mass table.
- Horecker and Kornberg, Journal of Biological Chemistry, 1948. Original determination of the 340 nm extinction coefficient of reduced pyridine nucleotide, 6,220 M⁻¹cm⁻¹; supports the redox-state check described here.
- USP General Chapter <621> Chromatography. Defines system suitability and the conditions under which retention-time comparison against a reference standard is a valid identification test.
- ICH Q2(R2), Validation of Analytical Procedures. Establishes specificity as a demonstrated property of a procedure, which is the basis for requiring evidence that a method resolves plausible confounders rather than asserting it.
